Japanese Circulation Society (JCS) in International Sessions
The JCS has close ties with the AHA. For example, the International Program Committee, which consists of 9 international scientists, including Professor Akira Matsumori from Japan, programmed the special international sessions. International Forums, including 1 from Japan, were held before the opening session. Each comprised 5 top abstracts and a featured presentation from 10 countries reporting the latest science from their country. International Forum Japan was moderated by Professor Hiroyuki Tsutsui and Professor Sidney C Smith. Professor Tohru Minamino gave a featured presentation about the relationship between aging and CV diseases, prompting lively discourse among the international discussants ( Figure 3A ). In addition, the AHA-JCS Joint Session's theme was the recent progress in interventional therapy for chronic total occlusion (CTO). Professor Yukio Ozaki, Professor Akihiko Usui, and Professor Yoshihiro Morino discussed the approach to CTO with the other international members ( Figure 3B ). In the Best of Other Cardiovascular Meetings (international), Professor Hiroaki Shimokawa, Editor-in-Chief of Circulation Journal, presented the current status of JCS and the growing number of citations of the Journal ( Figure 3C ). JCS also featured a booth in the Science & Technology Hall to advertise JCS activities to the AHA attendees ( Figure 3D ).
Late-Breaking Clinical Trials and Clinical Science: Special Reports
Updates of results from the most recent clinical trials were the highlight of the 2012 AHA Scientific Sessions, with 27 late- 
Practice Implications for Coronary Artery Disease (CAD) and Venous Thromboembolism (VTE)
FREEDOM For diabetic patients in the FREEDOM trial with multivessel CAD, coronary artery bypass graft surgery (CABG) was significantly more effective than percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) (paclitaxelor sirolimus-eluting stent). 4 The total number of participants was 1,900. For the primary outcome (death, stroke, or nonfatal myocardial infarction (MI)), the 5-year event rates were 18.7% for CABG and 26.6% for the PCI group (P=0.005) ( Figure 4B ). The rates of total deaths and MI were lower in the CABG group than in the PCI group (10.9% vs. 16.3%, P=0.049 and 6.0% vs. 13.9%, P<0.0001, respectively). Only the stroke rate was higher in the CABG group (5.2% vs. 2.4% for PCI group, P=0.034). The relative reduction was 27.7% (power=80%). The secondary outcomes, including major adverse cardiac and CV events (death, MI, stroke, or repeat revascularization) at 1 year were lower in the CABG-treated group than in the PCI group (106 vs. 157). In the United States, CABG costs $8,622 more than DES-PCI at initial cost; however, the better outcome makes CABG more cost-effective and worth the front-end expense.
ASPIRE Patients with idiopathic VTE have increased risk of recurrence after cessation of primary anticoagulation therapy. The Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) study to determine if low-dose aspirin is effective in preventing the recurrence of VTE found no significant difference between the aspirin and placebo groups at primary endpoint (symptomatic deep vein thrombosis or pulmonary embolism). The aspirin group had suppression of the 2 prespecified secondary endpoints: (1) recurrent VTE, MI, stroke, CV death: hazard ratio (HR)=0.66 (P=0.01); and (2) recurrent VTE, MI, stroke, major bleeding or death from any cause: HR=0.67 (P=0.01). 5 ARCTIC The randomly assigned 2,440 patients in this study underwent either antiplatelet drug adjustment or conventional strategy before stent implantation and in the outpatient clinic 2-4 weeks later. If patients showed high platelet reactivity under the administration of traditional dual antiplatelet therapy, they had an additional dose of clopidogrel, prasugrel, or aspirin, together with glycoprotein IIb/IIIa inhibitors. No significant improvements in the primary or secondary outcomes were seen. 6 TRILOGY-ACS Patients on medication (clopidogrel or prasugrel) for unstable angina or non-ST-elevated acute coronary syndrome (ACS) were additionally administered aspirin to prevent CV events. Platelet reactivity was measured with P2Y reaction units in 28% patients. High platelet activity indicated an increase risk for ischemic events (P=0.017). Prasugrel lowered platelet reactivity (greater platelet inhibition) more than clopidogrel. However, prasugrel did not show an advanced TACT The Trial to Assess Chelation Therapy (TACT) is the first randomized, clinical study to assess the effect of chelation therapy in preventing CV events in patients with a prior MI. Chelation therapy resulted in a significant reduction of serious CV events (HR=0.82, P=0.035), but the positive effects were mainly in patients with diabetes or anterior MI.
Treatments for Prevention of CV Events
FORWARD and OPERA n-3 PUFA (omega-3 fatty acid) was investigated for preventing recurrent atrial fibrillation (AF) (FORWARD trial) or AF incidence following heart surgery (OPERA trial). 8 No significant difference was documented between the fish oil and placebo groups in both studies.
Novel Treatments for Managing Lipid Disorders
Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) promotes the degradation of low-density lipoprotein (LDL) receptors and increased LDL cholesterol (LDL-C) levels in blood. PCSK9 inhibitors thus theoretically increase LDL receptors and reduce LDL-C. The RUTHERFORD, GAUSS, and RN316 trials evaluated anti-PCSK9 antibodies to reduce LDL-C. Dalcetrapib is an inhibitor of the cholesterylester transfer protein, which raises HDL-C. The dal-OUTCOMES Phase 3 clinical trial was also presented.
RUTHERFORD This study comprised patients with heterozygous familial hypercholesterolemia showing 100 mg/dl more (LDL-C) and 400 mg/dl less triglycerides with statin and ezetimibe treated with a dose of anti-PCSK9 monoclonal antibody (AMG145: 350 mg or 420 mg or placebo) every 4 weeks. Patients showed reduced LDL-C levels at 12 weeks (−43%, −55% vs. +1%, P<0.001). 9 GAUSS In this study, 160 statin-intolerant patients were randomly assigned to a control group (placebo and ezetimibe) or treatment group (anti-PCSK9: AMG145 280 mg, 350 mg, 420 mg, and 420 mg in combination with 10 mg ezetimibe). The proportion of patients with less than 100 mg/dl LDL-C in the treatment group was greater than that in the control group (47%, 53%, 61%, 63% vs. 7%). 10 dal-OUTCOMES In this study, 7,938 patients received dalcetrapib 600 mg and 7,933 patients received placebo after recent ACS. The study was terminated at 3 years because the CV incidence of patients on dalcetrapib was 9.2%, and that of patients on placebo was 9.1% (HR=1.04, P=0.52). No significant association was recognized between baseline HDL-C and CV risk. 
Cell-Based Therapies for Myocardial Regeneration
Cell therapies for CV diseases have been major topics at AHA meetings. The cell sources and cell survival are now the focus of investigations to achieve significant improvements in cardiac function.
SWISS AMI Patients who had lower left ventricular ejection fraction (LVEF <45%) after ST-elevated MI and primary PCI were treated with intracoronary injection of bone marrowderived mononuclear cells (BM-MNC) at 5-7 days or 3-4 weeks after PCI. Intracoronary injection of BM-MNC did not improve LVEF at 4 months as shown by cardiac MRI.
ALCADIA Cardiac-derived stem cells (CSCs) were isolated and injected with gelatin hydrogel and basic fibroblast growth factor, in combination with CABG. Only 6 patients were enrolled: 1 patient had congestive heart failure and the other 5 patients showed improved LVEF by MRI at 6 months (P=0.0117).
POSEIDON In this study, 30 patients with LV dysfunction because of ischemic cardiomyopathy were randomized into the allogeneic or autologous BM-derived mesenchymal stem cells (MSC) group. Both groups showed reduced mean early enhancement defect (ie, infarct size) on CT by −33.21% (P<0.001), although the improvement in LVEF was not significant. 12
Management of LV Dysfunction: Devices and Drugs
MADIT-RIT A total of 1,500 patients with an implantable cardioverter-defibrillator were randomly assigned to 1 of 3 programs of antitachycardia pacing: (1) high-rate therapy -2.5-s delay before the initiation of therapy at a heart rate ≥200 beats/min; (2) delayed therapy -60-s delay at 170-199 beats/min; (3) conventional programming -2.5-s delay at 170-199 beats/min and 1.0-s delay at ≥200 beats/min. The highrate or the delayed therapy significantly reduced a first occurrence of inappropriate therapy in comparison with conventional therapy (P<0.001), and also decreased all-cause mortality (high- RELAX-AHF Serelaxin is a recombinant human relaxin-2, which is a vasoactive peptide hormone. The 1,161 patients admitted to hospital for acute heart failure in 11 countries were randomized to the serelaxin or placebo group. Serelaxin (30 mg · kg -1 · day -1 ) were administered intravenously up to 48 h. The dyspnea improvement was evaluated with the visual analog scale area under the curve (VAS AUC) from baseline to day 5. The serelaxin group showed a marked improvement in AUC. For the second endpoint, CV death or readmission to hospital for heart failure or renal failure was evaluated at 60 days, but was not significantly different between groups. However, serelaxin significantly reduced CV death (6.1% vs. 9.6% HR=0.63, P=0.028) and all-cause death at 180 days (7.3% vs. 11.3% HR=0.63, P=0.02). 14 
Clinical Science: Special Reports
LoDoCo Patients with CAD were randomly assigned to low-dose colchicine (0.5 mg/day) treatment group or placebo group to investigate the inhibition of neutrophil-mediated inflammation in CAD. Colchicine reduced the risk of primary outcome (ACS, out-of-hospital cardiac arrest, and non-cardioembolic ischemic stroke) (5.3% vs. 16%, HR=0.33, P<0.001).
Basic Science
Basic science updates in CV medicine were the other AHA highlight for 2012, with exciting and novel findings reported in both oral and poster sessions ( Figure 5A ). Mitochondrial functional studies (mitochondrial biogenesis, novel mechanism of cell death, autophagy, mitochondrial fission and fusion) were actively discussed. Professor Richard N. Kitsis presented a new mechanism of necrosis. Bcl-2 family members (Bax/Bak) known to regulate apoptosis via mitochondrial outer membrane permeabilization were also found to control necrosis by opening the mitochondrial permeability transition pore in the inner membrane. 15 Mitochondria were therefore identified to be a key regulator not only for apoptosis, but also for necrosis. MicroRNA (miRNA) was also presented as an important topic in heart failure. In the oral session, "Cardiac Failure and Remodeling: miRNA and Proteomics", several groups reported that miRNAs were important mediators of heart failure, and long, noncoding RNA was also suggested to be critical in the pathogenesis of heart failure. Genetic and epigenetic analyses of the cell biology of human heart diseases were very popular in this scientific session. In the CV seminar, "Frontiers in Genomics in Cardiovascular Disease", genome-wide association studies (GWAS) were the focus. CAD, MI, sudden cardiac death, and stroke have been analyzed by GWAS, which are useful for finding novel genetic markers and could change CV medicine from the genomic aspect. Epigenetic changes to heart cells have also become more critical for revealing the mechanisms of heart failure. In an evening session, "Genomic Plasticity: Implications for Cardiovascular Disease", single-nucleotide polymorphisms, histone modification, chromatin structural protein, and DNA methylation were actively discussed. Genetic and epigenetic modification in CV disease is now clearly placed in the center of the cardiology field.
Nobel Laureate lecture
Nitric oxide (NO) is an important gas for maintaining the integrity of heart and blood vessels. In 1998, 3 investigators were awarded the Nobel Prize in physiology or medicine for their research into NO, and Professor Louis Ignarro, PhD, FAHA, gave the 2012 lecture to discuss his journey to Stockholm. Basically, he initially found that NO activates guanylate cyclase to increase cyclic guanosine monophosphate, and then discovered that the endothelium-derived relaxing factor was NO.
Regenerative Medicine for CV Diseases and
Induced Pluripotent Stem Cells . FUJITA J potential cell sources. 16 Professor Shinya Yamanaka, who was the innovator of iPSCs, was awarded a Nobel Prize just a few weeks before the 2012 AHA Scientific Sessions, and several sessions focused on how to use iPSCs and translate iPSCs to clinical trials ( Figure 5B ). "How to Make an Inducible Pluripotent Stem Cell" was the representative session covering the great interest in iPSCs. In a special session, "iPS Cells as Personalized Research Platforms", the investigators addressed how to use iPSCs for CV medicine. Professor Jianyi Zhan talked about a preclinical study of a fibrin patch with iPSCs and porcine MI model, and described the difficulty in keeping iPSCs alive in xenotransplantation. Professor Luis Santana, Professor Lior Gepstein, and Professor Joseph Wu presented the disease models of iPSCs, which were Timothy syndrome, long QT syndrome, Pompe disease, hypertrophic cardiomyopathy, and dilated cardiomyopathy. Professor Charles Murry finally summarized the advanced technologies involving iPSCs, such as zinc finger nucleases. Some clinical trials in this area are ongoing; however, in general, large clinical trials have failed to show a marked improvement in cardiac function, despite most of the basic studies using small-animal models, such as mice or rats, showed a prominently significant improvement in cardiac function (>10% increase in LVEF) with cell therapies. 17 The valley of death between basic and clinical research in stem cell therapy demands the necessity for preclinical studies with large-animal models. The "Tissue-Engineered Heart Repair" session focused on how to achieve functional repair following the loss of large numbers of cardiomyocytes. In "Telling Stem Cells What to Do Without Getting Lost", successful long-term survival of transplanted stem cells was discussed. Allogeneic stem cells were more advantageous than xenotransplantation, and hESCs and hiPSCs triggered a strong immune reaction in a porcine model. Professor Philippe Menasche finally presented that induced immunological tolerance therapies, such as HLA gene modification or regulatory T cell therapy, were necessary for xenotransplantation models in preclinical studies with a large-animal model. If autologous transplantation of iPSCs from patients themselves were possible, it would be the best therapy without immunological rejection for CV regenerative medicine.
Closing Remarks
Recently, the European Society of Cardiology has been gaining popularity among Japanese CV researchers, and the AHA Scientific Sessions did not appear as major as in past years. However, the 2012 Scientific Sessions in this year was more active and much better attended than recent AHA meetings. The success of the meeting was attributed not only to the popularity of Los Angeles, but also to the AHA's continuous efforts in progressing the CV sciences. Many Japanese projects were presented, which increased the quality of basic and clinical sciences in the AHA Scientific Sessions 2012. I sensed how important Japanese CV research is to the worldwide progress in the field, and I believe that the JCS contribution will be more and more critical to the AHA.
